Bayer's Two-Speed Story: Q2 Beat Lifts the Shares While the Glyphosate Clock Keeps Sliding
Published on 08/09/2026 at 08:41 | Redaktion boerse-global.de
The market's attention has been split between two very different narratives at Bayer this week: a quarterly performance that has analysts scrambling to lift their price targets, and a legal calendar that keeps pushing the glyphosate resolution further down the road.
The Leverkusen-based group reported second-quarter numbers on Tuesday that came in ahead of consensus. Currency- and portfolio-adjusted sales rose 2.2 percent to EUR 10.87 billion, while adjusted EBITDA advanced 1.9 percent to EUR 2.14 billion. The bottom line swung to a net profit of EUR 219 million, a sharp turnaround from the EUR 199 million loss posted in the same period a year earlier. Management also trimmed its net financial debt target to a corridor of EUR 29 to 30 billion.
Crop Science carries the load
The standout performance came from the Crop Science division, where operating profit jumped by nearly a third to EUR 902 million. Efficiency programmes are clearly gaining traction, and the unit also benefited from robust demand for Dicamba soybean seed in the US. In the pharmaceuticals business, growth from Nubeqa and Kerendia offset declining sales of the anticoagulant Xarelto, leaving the division with a mixed but broadly stable picture.
The numbers offer a glimpse of operational strength emerging after years in which litigation overhangs and balance-sheet concerns dominated the investment case.
Analysts move in unison
The earnings beat triggered a swift response from the sell-side. Goldman Sachs' James Quigley raised his price target from EUR 62.50 to EUR 63.50 on Wednesday, keeping a buy recommendation and pointing to the strong operational momentum. UBS went a step further, upgrading the stock from "Neutral" to "Buy" and lifting its target from EUR 52.00 to EUR 62.00, arguing that core earnings had comfortably beaten expectations. A third bank also increased its fair value to EUR 60.00, citing the reduced net debt and operational progress. Targets across the Street now sit in a range of EUR 60 to EUR 63.50, comfortably above the current share price.
While Bayer's operational recovery is turning a corner, your own business's risk management deserves the same scrutiny. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace hazards properly and stay compliant. Download the free Risk Assessment Toolkit
The legal calendar slips once more
Yet the glyphosate saga remains very much part of the equation. The court in Missouri has postponed the hearing on final approval of the multi-billion-dollar class settlement to 14 September 2026. The settlement, worth up to USD 7.25 billion and structured to run over 21 years, has hit a procedural snag: legal questions around claimant opt-outs that arose in the wake of a US Supreme Court ruling. That ruling, handed down in late June, determined that federal EPA approval requirements take precedence over state-level warning obligations — a decision that strips the legal foundation from many pending glyphosate claims.
For investors, the delay means the path to full clarity on litigation risk remains open until the autumn. The earlier postponement of a hearing had already fuelled speculation that settlement talks were intensifying; the new date suggests the process is grinding forward, albeit at a measured pace.
Momentum builds, but the old high remains in sight
The market has taken the combination of solid results and analyst endorsements in its stride. By Friday's close, the shares stood at EUR 49.90, up 1.05 percent on the day and 3.14 percent over the past seven sessions. Since the start of the year, the stock has gained 34.83 percent. That leaves it 7.35 percent shy of the 52-week high of EUR 53.86 touched in early July. Technical indicators point to room for further upside, with the RSI at 63.6 — elevated but not yet in overbought territory.
The September hearing now looms as the next major catalyst. Until then, the operational recovery looks set to remain the primary driver of the share price, with the legal overhang gradually receding into the background.
Just as Bayer's legal overhang gradually recedes, you can clear your own compliance burdens. Over 37,000 UK businesses trust this free Health & Safety Toolkit with risk assessments, checklists and toolbox talks that cover COSHH, PUWER and the Health & Safety at Work Act 1974. Get the free Health & Safety Toolkit
